Table 5.

Cox regressions of glioma survival by tumor EGFR, MDM2, and TP53 genetic and expression alterations, San Francisco Bay Area Adult Glioma Study, 1991-2000

GlioblastomaAnaplastic astrocytoma
n *n died Median mos survival P, HR (95% CI) §n *n died Median mos survival P, HR (95% CI) §
EGFR amplification4003997055
    No2512506.80.46564120.30.04
    Yes1491497.90.93 (0.75-1.14)14144.52.31 (1.04-5.12)
EGFR expression4094088267
    Negative2162166.90.008554220.60.0001
    Positive1931927.80.76 (0.63-0.93)27259.92.97 (1.70-5.19)
MDM2 amplification4003987055
    No3623607.20.04695416.3NC
    Yes38387.20.70 (0.49-0.98)1110.6
MDM2 expression 4134128165
    No stain1221227.0473719.4
    <5%1171168.0211619.1
    5-30%1011016.60.1412114.00.003
    >30%73737.41.07 (0.98-1.18)1130.11.81 (1.22-2.70)
MDM2 Expression
    Negative1221227.00.28473719.40.14
    Positive2912907.31.13 (0.91-1.40)342811.31.53 (0.87-2.67)
TP53 expression4354338567
    No stain72727.2232111.0
    <5%1231228.0151212.6
    5-30%1171177.30.05191519.10.47
    >30%1231226.81.10 (1.00-1.21)281920.30.93 (0.75-1.15)
TP53 expression
    Negative72727.20.38232111.00.64
    Positive3633617.31.12 (0.87-1.45)624619.50.87 (0.50-1.54)
TP53 mutation4074057658
    No mutation3453437.20.54494111.30.43
    Mutation62628.41.09 (0.83-1.44)271736.60.78 (0.42-1.46)
  • Abbreviations: NC, not calculated; 95% CI, Confidence Interval; HR, Hazard Ratio

  • * Number of cases.

  • Number of deceased.

  • Kaplan-Meier estimates of median months survival.

  • § HR adjusted for age, gender, ethnicity (White/non-White), series, radiation (given/not given), surgery (resection/biopsy only), chemotherapy (given/not given).

  • HR results for tumor immunohistochemistry marker coded ordinally: 0, no stain; 1, <5%; 2, 5-30%; and 3, >30%;